Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Don Miller who wrote (3036)	5/26/1999 3:32:00 PM
From: j_fir2	Respond to of 10280

Will you look at that! Up 4+! It's a thing of beauty! (I didn't get my order filled at 58.5...)

To: Don Miller who wrote (3036)	5/26/1999 3:35:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 10280

>> I am puzzled by your comment. << Why? >> Have I miss interpreted << I don't know her, so I can't comment on whether or not you have her. >> Please enlarge and comment on why you think Tanox's drug is not a business threat. << The project failed in its first phase II trial, and 600 mg of antibody isn't cheap. The product, if approved, will be expensive. Some patients don't like needles. On a scale of 0 for no symptoms and 3 for severe symptoms, a decrease in ocular symptoms of 0.09 isn't exactly overwhelming. Few will opt, IMO, for limited efficacy relative to a good antihistamine, given that it requires two visits to a doc. I have moderate allergy problems with rather acute ocular issues. A good antihistamine and eye drops from Alcon (over the counter) allow me to lead a completely symptom-free life. I have no interest in visiting a physician's office for expensive biologicals, and feel that a majority of patients will think like me. Trials can be powered to make small contributions "significant". I believe that, if FDA likes the data, GNE will do well with anti-IgE. However, I don't feel that it will make a significant dent in antihistamines. It could even expand the market.